Hypoloc

Nebivolol, the active ingredient in Hypoloc, is a selective β1‑adrenergic antagonist presented as an oral tablet for oral use. It reduces heart rate, cardiac output and peripheral vascular resistance, making it useful for managing hypertension and for supporting treatment of chronic heart failure in adults.

GNH USA supplies Hypoloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets across Europe, Asia and the Americas.

Nebivolol is a selective β1‑blocker used in cardiovascular disease management.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of cardiovascular events. Chronic heart failure: improves left ventricular ejection fraction and decreases hospitalization rates. Heart failure with reduced ejection fraction: enhances cardiac output and alleviates symptoms of fluid overload.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Fatigue or tiredness - Headache - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Nausea or mild gastrointestinal upset - Peripheral edema

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm in patients with asthma or COPD - Acute heart failure decompensation - Allergic reactions including rash or angioedema - Hepatic dysfunction or elevated liver enzymes

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Dose adjustment in renal impairment: reduce the dose according to renal function. Monitor heart rate: avoid use if resting heart rate is below 60 bpm. Caution in asthma or COPD: beta‑blockade may exacerbate bronchospasm. Avoid abrupt discontinuation: taper the dose to prevent rebound hypertension. Drug interactions: review concomitant medications, especially CYP2D6 inhibitors. Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Nebivolol can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Concomitant use with non‑selective beta‑blockers: additive bradycardia. - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma levels. - Combined use with calcium‑channel blockers verapamil or diltiazem: risk of severe bradycardia and AV‑block.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect. - Other antihypertensives (ACE inhibitors, ARBs): additive blood‑pressure lowering. - Insulin or oral hypoglycemics: nebivolol may mask hypoglycaemia symptoms.